Aims We tested the hypothesis that initiation versus non-initiation of sacubitril/valsartan is
associated with a more favorable subsequent change in left ventricular ejection fraction …

Sacubitril/valsartan is superior to enalapril in reducing the risks of cardiovascular death and
preventing hospitalization in patients with heart failure and reduced ejection fraction …

Background: Sacubitril-valsartan has been shown to improve morbidity and mortality in heart
failure patients with reduced left ventricular (LV) ejection fraction (EF). However, there is little …

Background Optimizing patients' health status is a primary goal for patients with heart failure
and reduced ejection fraction (HFrEF). The association of sacubitril/valsartan (ARNI) with …

Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor,
received US Food and Drug Administration approval in 2015 for heart failure with reduced …

Aims Practice guidelines recommend sacubitril/valsartan for heart failure with reduced
ejection fraction. The aim of our study was to describe the use of sacubitril/valsartan in real …

Sacubitril/valsartan has become an important first-line drug for symptomatic heart failure
(HF) patients, especially with left ventricular (LV) ejection fraction (LVEF)< 50%. However …

Aims We evaluated the clinical outcomes and trajectory of cardiac reverse remodelling
according to the timing of sacubitril/valsartan (Sac/Val) use in patients with heart failure (HF) …

Background In patients with heart failure with reduced ejection fraction (HFrEF), treatment
with sacubitril–valsartan (S/V) may reverse left ventricular remodeling (rLVR). Whether this …

Abstract Aims The PARADIGM-HF and PARAGON-HF trials tested sacubitril/valsartan
against active controls given renin–angiotensin system inhibitors (RASi) are ethically …